New Zealand markets open in 5 hours 30 minutes

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7600-0.0200 (-1.12%)
At close: 04:00PM EDT
1.8400 +0.08 (+4.55%)
After hours: 07:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 119.69M
Enterprise value -247.43M
Trailing P/E 2.51
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.32
Price/book (mrq)0.28
Enterprise value/revenue -0.65
Enterprise value/EBITDA -6.20

Trading information

Stock price history

Beta (5Y monthly) -0.93
52-week change 3-93.82%
S&P500 52-week change 322.36%
52-week high 330.5000
52-week low 31.7000
50-day moving average 37.1608
200-day moving average 314.9507

Share statistics

Avg vol (3-month) 33.34M
Avg vol (10-day) 32.36M
Shares outstanding 568.01M
Implied shares outstanding 671.59M
Float 850.97M
% held by insiders 115.12%
% held by institutions 1104.21%
Shares short (15 Apr 2024) 46.51M
Short ratio (15 Apr 2024) 42.43
Short % of float (15 Apr 2024) 410.54%
Short % of shares outstanding (15 Apr 2024) 49.58%
Shares short (prior month 15 Mar 2024) 45.09M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 12.94%
Operating margin (ttm)1.78%

Management effectiveness

Return on assets (ttm)5.34%
Return on equity (ttm)12.73%

Income statement

Revenue (ttm)380.79M
Revenue per share (ttm)5.66
Quarterly revenue growth (yoy)395.50%
Gross profit (ttm)N/A
EBITDA 39.89M
Net income avi to common (ttm)49.27M
Diluted EPS (ttm)0.7000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)371.36M
Total cash per share (mrq)5.48
Total debt (mrq)4.24M
Total debt/equity (mrq)0.98%
Current ratio (mrq)5.66
Book value per share (mrq)6.52

Cash flow statement

Operating cash flow (ttm)11.92M
Levered free cash flow (ttm)38.36M